VivoSim Labs Inc VIVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.18
- Day Range
- $0.17–0.18
- 52-Week Range
- $0.17–3.41
- Bid/Ask
- $0.18 / $0.18
- Shares Outstanding
- 16.59M
- Market Cap
- $2.40M
- Volume/Avg
- 167,196 / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.organovo.com
Valuation
|
Metric
|
VIVS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 4.44 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VIVS
|
|---|---|
Quick Ratio | 1.43 |
Current Ratio | 1.70 |
Interest Coverage | −1,045.00 |
Quick Ratio
VIVS
Profitability
|
Metric
|
VIVS
|
|---|---|
Return on Assets (Normalized) | −151.65% |
Return on Equity (Normalized) | −343.44% |
Return on Invested Capital (Normalized) | −299.40% |
Return on Assets
VIVS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|lrZKbJ | LOCK|^kH@ | $129B | |||
| Moderna Inc
MRNA
| LOCK|c!dHtm | LOCK|Z^^ | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^n$N?v% | LOCK|<#WSS | $77B | |||
| argenx SE ADR
ARGX
| LOCK|v&n%#!x | LOCK|^hn | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&?ZdJ% | LOCK|%W | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#k$>c? | LOCK|$!@w? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>LJ@!yx | LOCK|B>lZ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|bZ!vWj< | LOCK|%k$ | $24B | |||
| Incyte Corp
INCY
| LOCK|&>L$!^# | LOCK|!%j | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%FPgc<$ | LOCK|zH | $14B |
United States